Decipherbio
Genomic Testing for Urological Cancers | Decipher Bio.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$600m Valuation: $600m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
DecipherBio, a subsidiary of Veracyte, specializes in genomic testing for prostate and bladder cancers, providing actionable insights to aid in treatment decisions. Operating within the United States, DecipherBio offers its services through CLIA-validated laboratory-developed tests (LDTs), which do not require FDA clearance. The company's core clients include urologists, radiation oncologists, and other healthcare providers who treat prostate and bladder cancer patients. DecipherBio's business model revolves around offering genomic tests that help physicians assess the risk of cancer progression and tailor treatment plans accordingly. Revenue is generated through the sale of these genomic tests to healthcare providers and institutions. DecipherBio plans to expand its reach globally by adapting its genomic testing to the nCounter Analysis System, allowing for broader access to its diagnostic tools. The company operates in the genomic diagnostics market, focusing on precision medicine to improve patient outcomes.
Keywords: Genomic testing, Prostate cancer, Bladder cancer, CLIA-validated, Laboratory-developed tests, Urologists, Radiation oncologists, Precision medicine, Diagnostic tools, Healthcare providers.